세계의 피부 섬유증 치료 시장 : 산업 분석, 시장 규모, 점유율, 성장 및 동향(2025-2032년)

Cutaneous Fibrosis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,052,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,300,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,994,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계의 피부 섬유증 치료 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 성장 촉진요인, 추세, 기회 및 억제요인 같은 중요한 시장 역학에 대한 철저한 평가를 제공하여 시장 구조에 대한 자세한 통찰력을 제공합니다. 이 연구 간행물은 2025년부터 2032년까지 글로벌 피부 섬유증 치료 시장의 예상 성장 궤적을 설명하는 독점 데이터와 통계를 제공합니다.

주요 인사이트

• 피부섬유증 치료 시장 규모(2025년) : 7억 3,200만 달러
• 시장 규모 예측(금액 기준, 2032년) : 11억 7,320만 달러
• 세계 시장의 성장률(CAGR, 2025-2032년) : 7.0%

피부 섬유증 치료 시장 : 분석 범위

피부 섬유증은 비정상적인 상처 치유 과정으로 인해 과도한 흉터와 조직 경화를 특징으로하는 병리학 적 상태입니다. 일반적으로 전신 경화증, 켈로이드 및 방사선 유발 섬유증과 같은 상태와 관련이 있습니다. 치료 방법은 코르티코스테로이드 및 항섬유화제를 포함한 약리학적인 개입부터 레이저 치료, 줄기세포 치료, 재생 의학 같은 첨단 치료법까지 다양합니다. 이 시장은 병원, 피부과 클리닉, 연구 기관 및 홈케어 환경을 대상으로 합니다. 시장 성장은 섬유성 피부 질환의 유병률 증가, 새로운 치료 접근법의 채택 증가, 재생 의학 및 생물학적 제제의 발전에 의해 주도되고 있습니다.

시장 성장 촉진요인

세계의 피부 섬유증 치료 시장은 경피증, 켈로이드, 방사선 유발 섬유증과 같은 질환의 발병률 증가를 비롯한 몇 가지 주요 요인에 의해 추진되고 있습니다. 피부과 연구에 대한 투자 증가와 함께 사용 가능한 치료 옵션에 대한 인식이 높아지면서 시장 확대에 기여하고 있습니다. 또한 새로운 생물학적 치료법, 유전자 기반 치료법, 항섬유화제의 도입으로 치료 효과가 향상되고 환자 치료 결과가 개선되고 있습니다. 줄기세포 치료와 혈소판 풍부 혈장(PRP) 치료를 포함한 재생 의학의 역할이 확대되면서 섬유성 피부 질환에 대한 혁신적인 치료 옵션을 제공함으로써 시장 성장을 더욱 촉진하고 있습니다.

시장 성장 억제요인

강력한 성장 전망에도 불구하고 피부 섬유증 치료 시장은 높은 치료 비용, 제한된 표적 치료제의 가용성, 신약 승인과 관련된 규제 장애물 등의 과제에 직면해 있습니다. 섬유증의 복잡한 병태생리로 인해 약물 개발이 어려워 임상시험 기간이 길어지고 R&D 비용이 증가합니다. 또한 표준화된 치료 프로토콜이 부족하고 첨단 치료법에 대한 보험 적용 범위가 제한되어 있어 특히 신흥 경제국에서는 시장 진출에 어려움을 겪고 있습니다. 이러한 장벽을 해결하려면 연구 협력 강화, 환급 체계 개선, 새로운 치료 방식에 대한 규제 지원이 필요합니다.

시장 기회

피부 섬유증 치료 시장은 개인 맞춤형 의학의 발전, 병용 요법의 채택 증가, 최소 침습적 치료 옵션의 확대에 힘입어 상당한 성장 기회를 제공합니다. 섬유증 치료에 AI 기반 진단 도구와 예측 모델링이 통합되면 조기 진단과 치료 효과가 향상될 것으로 예상됩니다. 또한, 항섬유화 약물 발견에 대한 연구가 증가하고 피부 침투력이 개선된 국소 치료제의 개발은 수익성 높은 시장 전망을 제공합니다. 제약회사와 연구기관 간의 전략적 파트너십은 혁신을 가속화하고 치료 접근성을 확대하는 데 중요한 역할을 할 것입니다.

이 보고서에서 답변을 얻을 수 있는 주요 질문

• 세계의 피부 섬유증 치료 시장의 성장을 가속하는 주요 요인은 무엇인가?
• 피부 섬유증 치료에 가장 많이 사용되는 치료 방법과 약물 클래스는 무엇인가?
• 기술 발전은 시장 경쟁 구도를 어떻게 형성합니까?
• 시장에 기여하는 주요 기업은? 시장의 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계의 피부 섬유증 치료 시장에서의 새로운 동향과 장래성은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
• COVID-19의 영향 분석
• 예측 요인 : 관련성과 영향

제3장 부가가치 통찰

• 제품 채택 분석
• 규제 상황
• 밸류체인 분석
• PESTLE 분석
• Porter's Five Forces 분석

제4장 세계의 피부 섬유증 치료 시장 전망

• 주요 하이라이트
  • 시장 규모와 전년대비 성장률(10억 달러)
  • 절대 수익 기회
• 시장 규모 분석과 예측(10억 달러)
  • 과거 시장 규모 분석(10억 달러, 2019-2024년)
  • 현재 시장 규모 분석과 예측(10억 달러, 2025-2032년)
• 세계의 피부 섬유증 치료 시장 전망 : 약제 클래스별
  • 소개 및 주요 조사 결과
  • 과거 시장 규모 분석 : 약제 클래스별(10억 달러, 2019-2024년)
  • 현재 시장 규모 분석과 예측 : 약제 클래스별(10억 달러, 2025-2032년)
    • 코르티코스테로이드
    • 항섬유화제
    • 면역 요법
      • 면역 글로불린
      • 면역 억제제
      • 야누스 키나아제(JAK) 억제제
      • 기타
  • 시장 매력 분석 : 약제 클래스별
• 세계의 피부 섬유증 치료 시장 전망 : 투여 경로별
  • 소개 및 주요 조사 결과
  • 과거 시장 규모 분석 : 투여 경로별(10억 달러, 2019-2024년)
  • 현재 시장 규모 분석과 예측 : 투여 경로별(10억 달러, 2025-2032년)
    • 경구
    • 주사제
    • 국소
  • 시장 매력 분석 : 투여 경로별
• 세계의 피부 섬유증 치료 시장 전망 : 적응증별
  • 소개 및 주요 조사 결과
  • 과거 시장 규모 분석 : 적응증별(10억 달러, 2019-2024년)
  • 현재 시장 규모 분석과 예측 : 적응증별(10억 달러, 2025-2032년)
    • 켈로이드
    • 경피증
    • 방사선 유발 섬유증
    • 만성 이식편 대 숙주병(GvHD) 관련 피부 섬유증
    • 기타
  • 시장 매력 분석 : 적응증별
• 세계의 피부 섬유증 치료 시장 전망 : 유통 채널별
  • 소개 및 주요 조사 결과
  • 과거 시장 규모 분석 : 유통 채널별(10억 달러, 2019-2024년)
  • 현재 시장 규모 분석과 예측 : 유통 채널별(10억 달러, 2025-2032년)
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장 매력 분석 : 유통 채널별

제5장 세계의 피부 섬유증 치료 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모 분석 : 지역별(10억 달러, 2019-2024년)
• 현재 시장 규모 분석과 예측 : 지역별(10억 달러, 2025-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제6장 북미의 피부 섬유증 치료 시장 전망

제7장 유럽의 피부 섬유증 치료 시장 전망

제8장 동아시아의 피부 섬유증 치료 시장 전망

제9장 남아시아 및 오세아니아의 피부 섬유증 치료 시장 전망

제10장 라틴아메리카의 피부 섬유증 치료 시장 전망

제11장 중동 및 아프리카의 피부 섬유증 치료 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 프로파일(상세 : 개요, 재무, 전략, 최근 동향)
  • Novartis AG
  • Pfizer
  • Sanofi
  • F. Hoffmann-La Roche(Genentech, Inc.)
  • Boehringer Ingelheim International GmbH
  • Jubilant Cadista
  • Horizon Therapeutics USA, Inc.
  • Bristol-Myers Squibb Company
  • Teva Pharmaceuticals
  • Amgen
  • Johnson &Johnson Services
  • AbbVie
  • Bayer
  • Merck &Co.
  • GlaxoSmithKline
  • LEO Pharma
  • Actelion Pharmaceuticals

제13장 부록

• 분석 방법
• 분석의 전제조건
• 두자어 및 약어

HBR

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global cutaneous fibrosis treatment market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cutaneous fibrosis treatment market from 2025 to 2032.

Key Insights:

• Cutaneous Fibrosis Treatment Market Size (2025E): USD 732.0 Million
• Projected Market Value (2032F): USD 1,173.2 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 7.0%

Cutaneous Fibrosis Treatment Market -

Report Scope:

Cutaneous fibrosis is a pathological condition characterized by excessive scarring and tissue hardening due to abnormal wound healing processes. It is commonly associated with conditions such as systemic sclerosis, keloids, and radiation-induced fibrosis. Treatment approaches range from pharmacological interventions, including corticosteroids and antifibrotic agents, to advanced therapies such as laser treatment, stem cell therapy, and regenerative medicine. The market caters to hospitals, dermatology clinics, research institutions, and homecare settings. Market growth is driven by increasing prevalence of fibrotic skin disorders, rising adoption of novel therapeutic approaches, and advancements in regenerative medicine and biologics.

Market Growth Drivers:

The global cutaneous fibrosis treatment market is propelled by several key factors, including rising incidence of conditions such as scleroderma, keloids, and radiation-induced fibrosis. Increasing awareness regarding available treatment options, coupled with growing investments in dermatological research, is contributing to market expansion. Additionally, the introduction of novel biologic therapies, gene-based treatments, and anti-fibrotic drugs is enhancing treatment efficacy and improving patient outcomes. The expanding role of regenerative medicine, including stem cell therapies and platelet-rich plasma (PRP) treatments, is further driving market growth by offering innovative treatment options for fibrotic skin disorders.

Market Restraints:

Despite strong growth prospects, the cutaneous fibrosis treatment market faces challenges, including high treatment costs, limited availability of targeted therapies, and regulatory hurdles associated with the approval of new drugs. The complex pathophysiology of fibrosis makes drug development challenging, leading to extended clinical trial durations and increased R&D expenditures. Additionally, the lack of standardized treatment protocols and limited insurance coverage for advanced therapies pose challenges for market penetration, particularly in emerging economies. Addressing these barriers requires increased research collaboration, improved reimbursement frameworks, and regulatory support for novel treatment modalities.

Market Opportunities:

The cutaneous fibrosis treatment market presents significant growth opportunities driven by advancements in personalized medicine, increasing adoption of combination therapies, and expansion of minimally invasive treatment options. The integration of AI-driven diagnostic tools and predictive modeling in fibrosis treatment is expected to enhance early diagnosis and treatment effectiveness. Furthermore, growing research in anti-fibrotic drug discovery and the development of topical therapies with improved skin penetration offer lucrative market prospects. Strategic partnerships between pharmaceutical companies and research institutes will play a vital role in accelerating innovation and expanding treatment accessibility.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the cutaneous fibrosis treatment market globally?
• Which treatment modalities and drug classes are witnessing the highest adoption in cutaneous fibrosis management?
• How are technological advancements shaping the competitive landscape of the market?
• Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global cutaneous fibrosis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global cutaneous fibrosis treatment market, including Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche Ltd., focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. Companies are investing in R&D to develop novel antifibrotic drugs, biologics, and stem cell-based therapies. Collaborations with academic institutions and biotechnology firms are accelerating drug discovery and clinical trials for emerging treatment options. Additionally, companies are expanding their global presence through strategic mergers, acquisitions, and partnerships to strengthen their product portfolios and enhance market penetration.

Key Companies Profiled:

• Novartis AG
• Pfizer
• Sanofi
• F. Hoffmann-La Roche (Genentech, Inc.)
• Boehringer Ingelheim International GmbH
• Jubilant Cadista
• Horizon Therapeutics USA, Inc.
• Bristol-Myers Squibb Company
• Teva Pharmaceuticals
• Amgen
• Johnson & Johnson Services
• AbbVie
• Bayer
• Merck & Co.
• GlaxoSmithKline
• LEO Pharma
• Actelion Pharmaceuticals

Key Segments Covered in Cutaneous Fibrosis Treatment Industry Research

Cutaneous Fibrosis Treatment Market by Drug Class:

• Corticosteroids
• Anti-fibrotic Drugs
• Immunotherapy
• Immunoglobulins

Cutaneous Fibrosis Treatment Market by Route of Administration:

• Oral
• Injectable
• Topical

Cutaneous Fibrosis Treatment Market by Indication:

• Keloid
• Scleroderma
• Radiation-induced Skin Fibrosis
• Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis

Cutaneous Fibrosis Treatment Market by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Cutaneous Fibrosis Treatment Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Cutaneous Fibrosis Treatment Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Cutaneous Fibrosis Treatment Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 4.3.3.1. Corticosteroids
    • 4.3.3.2. Anti-fibrotic Drugs
    • 4.3.3.3. Immunotherapy
      • 4.3.3.3.1. Immunoglobulins
      • 4.3.3.3.2. Immunosuppressants
      • 4.3.3.3.3. Janus Kinase (JAK) Inhibitors
      • 4.3.3.3.4. Others
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Cutaneous Fibrosis Treatment Market Outlook: Route of Administration
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn), By Route of Administration, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 4.4.3.1. Oral
    • 4.4.3.2. Injectable
    • 4.4.3.3. Topical
  • 4.4.4. Market Attractiveness Analysis: Route of Administration
• 4.5. Global Cutaneous Fibrosis Treatment Market Outlook: Indication
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 4.5.3.1. Keloid
    • 4.5.3.2. Scleroderma
    • 4.5.3.3. Radiation-induced Skin Fibrosis
    • 4.5.3.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 4.5.3.5. Others
  • 4.5.4. Market Attractiveness Analysis: Indication
• 4.6. Global Cutaneous Fibrosis Treatment Market Outlook: Distribution Channel
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 4.6.3.1. Hospital Pharmacies
    • 4.6.3.2. Retail Pharmacies
    • 4.6.3.3. Online Pharmacies
  • 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Global Cutaneous Fibrosis Treatment Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia & Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Cutaneous Fibrosis Treatment Market Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By Indication
  • 6.2.5. By Distribution Channel
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 6.4.1. Corticosteroids
  • 6.4.2. Anti-fibrotic Drugs
  • 6.4.3. Immunotherapy
    • 6.4.3.1. Immunoglobulins
    • 6.4.3.2. Immunosuppressants
    • 6.4.3.3. Janus Kinase (JAK) Inhibitors
    • 6.4.3.4. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 6.5.1.
    • 6.5.1.1. Oral
    • 6.5.1.2. Injectable
    • 6.5.1.3. Topical
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 6.6.1.
    • 6.6.1.1. Keloid
    • 6.6.1.2. Scleroderma
    • 6.6.1.3. Radiation-induced Skin Fibrosis
    • 6.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 6.6.1.5. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 6.7.1.
    • 6.7.1.1. Hospital Pharmacies
    • 6.7.1.2. Retail Pharmacies
    • 6.7.1.3. Online Pharmacies
• 6.8. Market Attractiveness Analysis

7. Europe Cutaneous Fibrosis Treatment Market Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By Indication
  • 7.2.5. By Distribution Channel
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 7.4.1. Corticosteroids
  • 7.4.2. Anti-fibrotic Drugs
  • 7.4.3. Immunotherapy
    • 7.4.3.1. Immunoglobulins
    • 7.4.3.2. Immunosuppressants
    • 7.4.3.3. Janus Kinase (JAK) Inhibitors
    • 7.4.3.4. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 7.5.1.
    • 7.5.1.1. Oral
    • 7.5.1.2. Injectable
    • 7.5.1.3. Topical
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 7.6.1.
    • 7.6.1.1. Keloid
    • 7.6.1.2. Scleroderma
    • 7.6.1.3. Radiation-induced Skin Fibrosis
    • 7.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 7.6.1.5. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 7.7.1.
    • 7.7.1.1. Hospital Pharmacies
    • 7.7.1.2. Retail Pharmacies
    • 7.7.1.3. Online Pharmacies
• 7.8. Market Attractiveness Analysis

8. East Asia Cutaneous Fibrosis Treatment Market Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By Indication
  • 8.2.5. By Distribution Channel
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 8.4.1. Corticosteroids
  • 8.4.2. Anti-fibrotic Drugs
  • 8.4.3. Immunotherapy
    • 8.4.3.1. Immunoglobulins
    • 8.4.3.2. Immunosuppressants
    • 8.4.3.3. Janus Kinase (JAK) Inhibitors
    • 8.4.3.4. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 8.5.1.
    • 8.5.1.1. Oral
    • 8.5.1.2. Injectable
    • 8.5.1.3. Topical
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 8.6.1.
    • 8.6.1.1. Keloid
    • 8.6.1.2. Scleroderma
    • 8.6.1.3. Radiation-induced Skin Fibrosis
    • 8.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 8.6.1.5. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 8.7.1.
    • 8.7.1.1. Hospital Pharmacies
    • 8.7.1.2. Retail Pharmacies
    • 8.7.1.3. Online Pharmacies
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Cutaneous Fibrosis Treatment Market Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By Indication
  • 9.2.5. By Distribution Channel
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 9.4.1. Corticosteroids
  • 9.4.2. Anti-fibrotic Drugs
  • 9.4.3. Immunotherapy
    • 9.4.3.1. Immunoglobulins
    • 9.4.3.2. Immunosuppressants
    • 9.4.3.3. Janus Kinase (JAK) Inhibitors
    • 9.4.3.4. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 9.5.1.
    • 9.5.1.1. Oral
    • 9.5.1.2. Injectable
    • 9.5.1.3. Topical
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 9.6.1.
    • 9.6.1.1. Keloid
    • 9.6.1.2. Scleroderma
    • 9.6.1.3. Radiation-induced Skin Fibrosis
    • 9.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 9.6.1.5. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 9.7.1.
    • 9.7.1.1. Hospital Pharmacies
    • 9.7.1.2. Retail Pharmacies
    • 9.7.1.3. Online Pharmacies
• 9.8. Market Attractiveness Analysis

10. Latin America Cutaneous Fibrosis Treatment Market Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By Indication
  • 10.2.5. By Distribution Channel
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 10.4.1. Corticosteroids
  • 10.4.2. Anti-fibrotic Drugs
  • 10.4.3. Immunotherapy
    • 10.4.3.1. Immunoglobulins
    • 10.4.3.2. Immunosuppressants
    • 10.4.3.3. Janus Kinase (JAK) Inhibitors
    • 10.4.3.4. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 10.5.1. Oral
  • 10.5.2. Injectable
  • 10.5.3. Topical
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 10.6.1. Keloid
  • 10.6.2. Scleroderma
  • 10.6.3. Radiation-induced Skin Fibrosis
  • 10.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 10.6.5. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 10.7.1.
    • 10.7.1.1. Hospital Pharmacies
    • 10.7.1.2. Retail Pharmacies
    • 10.7.1.3. Online Pharmacies
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Route of Administration
  • 11.2.4. By Indication
  • 11.2.5. By Distribution Channel
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 11.4.1. Corticosteroids
  • 11.4.2. Anti-fibrotic Drugs
  • 11.4.3. Immunotherapy
    • 11.4.3.1. Immunoglobulins
    • 11.4.3.2. Immunosuppressants
    • 11.4.3.3. Janus Kinase (JAK) Inhibitors
    • 11.4.3.4. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 11.5.1. Oral
  • 11.5.2. Injectable
  • 11.5.3. Topical
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 11.6.1. Keloid
  • 11.6.2. Scleroderma
  • 11.6.3. Radiation-induced Skin Fibrosis
  • 11.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 11.6.5. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 11.7.1. Hospital Pharmacies
  • 11.7.2. Retail Pharmacies
  • 11.7.3. Online Pharmacies

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Novartis AG
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Pfizer
  • 12.3.3. Sanofi
  • 12.3.4. F. Hoffmann-La Roche (Genentech, Inc.)
  • 12.3.5. Boehringer Ingelheim International GmbH
  • 12.3.6. Jubilant Cadista
  • 12.3.7. Horizon Therapeutics USA, Inc.
  • 12.3.8. Bristol-Myers Squibb Company
  • 12.3.9. Teva Pharmaceuticals
  • 12.3.10. Amgen
  • 12.3.11. Johnson & Johnson Services
  • 12.3.12. AbbVie
  • 12.3.13. Bayer
  • 12.3.14. Merck & Co.
  • 12.3.15. GlaxoSmithKline
  • 12.3.16. LEO Pharma
  • 12.3.17. Actelion Pharmaceuticals

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료